Cencora Set to Purchase Majority Stake in OneOncology for Approximately $5 Billion
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 15 2025
0mins
Source: NASDAQ.COM
Acquisition Details: Cencora, Inc. has agreed to acquire the majority of OneOncology's equity interests from TPG for approximately $5 billion, valuing OneOncology at an enterprise value of $7.4 billion.
Financial Implications: The deal includes retiring OneOncology's $1.3 billion corporate debt and is expected to close by the end of Cencora's fiscal 2026 second quarter, with adjusted EPS likely falling toward the lower end of guidance.
Strategic Goals: This acquisition aligns with Cencora's pharmaceutical-centric strategy, enhancing specialty solutions and partnerships with oncology providers to improve patient access to innovative treatments.
Long-term Outlook: Cencora has raised its long-term growth forecasts, expecting adjusted operating income growth of 7% to 10% and adjusted EPS growth of 10% to 14%, driven by the contributions from OneOncology.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy COR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on COR
Wall Street analysts forecast COR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for COR is 394.00 USD with a low forecast of 360.00 USD and a high forecast of 417.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
9 Buy
1 Hold
0 Sell
Strong Buy
Current: 356.140
Low
360.00
Averages
394.00
High
417.00
Current: 356.140
Low
360.00
Averages
394.00
High
417.00
About COR
Cencora, Inc. is a global pharmaceutical sourcing and distribution services company. The Company helps both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. The Company operates through two segments: U.S. Healthcare Solutions and International Healthcare Solutions. The U.S. Healthcare Solutions segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, long-term care and alternate site pharmacies, and other customers. The International Healthcare Solutions segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cigna Corp Analysts Upgrade to 51% Upside, Healthcare Stocks Show Strong Growth
- Cigna's Strong Performance: Cigna Corp (NYSE:CI) leads with a 51.0% analyst upside and a remarkable 145.5% EPS growth forecast, showcasing its strong performance as a 'cash flow machine' that remains undervalued, poised for significant shareholder returns.
- Regeneron's Innovation Strength: Regeneron Pharmaceuticals Inc (F:REGN) ranks second with a 26.0% analyst upside and 21.5% projected EPS growth, recognized for its high-margin innovation in the biopharmaceutical sector, supporting its optimistic future growth prospects and industry leadership.
- Cencora's Distribution Edge: Cencora Inc (NYSE:COR), formerly AmerisourceBergen, secures third place with a 23.1% analyst upside and an impressive 120.0% EPS growth forecast, leveraging its extensive distribution network and strategic positioning in healthcare logistics for significant competitive advantages.
- Merck's Stable Growth: Merck & Company Inc (NYSE:MRK) rounds out the list with a 21.2% analyst upside potential and 34.2% projected EPS growth, described as a 'defensive pharma leader' that offers stability alongside growth potential through its diverse pharmaceutical portfolio, providing multiple revenue streams to mitigate market volatility.
Continue Reading
Cencora Elects Ellen Cooper as Independent Director Effective January 20, 2026
- New Board Member: Cencora has appointed Ellen Cooper as an independent director, effective January 20, 2026, aiming to enhance the board's expertise to support the company's sustainable growth.
- Industry Leader Background: Ellen Cooper brings extensive experience from the insurance sector, having served as CEO of Lincoln Financial, where she gained expertise in risk management and investment, expected to provide strategic guidance to Cencora.
- Education and Credentials: Cooper holds a Bachelor of Business Administration from Temple University and possesses multiple professional qualifications, including Fellow of the Society of Actuaries and Chartered Financial Analyst, further enhancing her value on the board.
- Alignment with Company Vision: Cencora's CEO Robert P. Mauch stated that Cooper's appointment will help strengthen the company's leadership position in global pharmaceutical solutions and advance its mission of creating healthier futures.
Continue Reading